A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)

NCT00258076 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Contraception
Female Contraception

Interventions

DRUG: EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.